Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Podofilox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podofilox SCHEMBL12377923 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL30947382 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10005569 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13663652 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10046308 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Epipodophyllotoxin SCHEMBL5792464 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL24049951 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL42243 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13661743 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL20807187 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611811-B1 | NEW PROCESS FOR PREPARING CYCLOLIGNANS | AXELAR AB (SE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2611811-B1 | NEW PROCESS FOR PREPARING CYCLOLIGNANS | AXELAR AB (SE) | 2017-01-18 | — | — | EP | disclosed |
| US-9314525-B2 | Picropodophyllin polymorph C and its use in cancer therapy | AXELAR AB (SE) | 2016-04-19 | — | — | US | disclosed |
| US-8987475-B2 | Process for preparing cyclolignans | Alexar AB (SE) | 2015-03-24 | — | — | US | disclosed |
| US-8987475-B2 | Process for preparing cyclolignans | Alexar AB (SE) | 2015-03-24 | — | — | US | disclosed |
| US-20130245285-A1 | New Process for Preparing Cyclolignans | AXELAR AB (SE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012030284-A1 | NEW PROCESS FOR PREPARING CYCLOLIGNANS | AXELAR AB (SE) | 2012-03-08 | — | — | WO | disclosed |
| US-20110178050-A1 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF A HYPERACTIVE IMMUNE SYSTEM | AXELAR AB (SE) | 2011-07-21 | — | — | US | disclosed |
| US-20100227797-A1 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES | AXELAR AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227797-A1 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES | AXELAR AB (SE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245285-A1 | New Process for Preparing Cyclolignans | CYP11B1, PPOX, CYP11B2 | LMNA 2558/4885CYP3A4 81/4885TUBB4A 1601/4885 |
| US-20110178050-A1 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF A HYPERACTIVE IMMUNE SYSTEM | HPGDS, ADCYAP1R1, HPD | LMNA 4875/4885CYP3A4 1076/4885TUBB4A 1704/4885 |
| US-20100227797-A1 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES | PPOX, PPIL1, PPID | LMNA 4019/4885CYP3A4 1351/4885TUBB4A 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.